Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Hepatic Porphyria: later-stage trial registry
1 of 3 indexed Acute Hepatic Porphyria trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Acute Hepatic Porphyria: 3 US clinical trials tracked, 1 recruiting.
Acute Hepatic Porphyria is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Alnylam Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition acute-hepatic-porphyria
OPEN 1 | RECR 33% | LATE 1 | EARLY 0 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Acute Hepatic Porphyria lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Hepatic Porphyria on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Hepatic Porphyria is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Alnylam Pharmaceuticals
NCT04883905
Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Vanderbilt University Medical Center
NCT05344599
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
Alnylam Pharmaceuticals
NCT03338816
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Hepatic Porphyria records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Hepatic Porphyria trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Hepatic Porphyria page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Acute Hepatic Porphyria trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alnylam Pharmaceuticals sponsors the most Acute Hepatic Porphyria trials on record, review their full trial history before evaluating a specific study. See Alnylam Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Hepatic Porphyria condition card totals 3 registered trials; most-linked intervention Givosiran; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.